We describe a kindred in which the proband and 6 of his 12 children have hypobetalipoproteinemia. The plasma lipoproteins of the affected subjects contained a unique species of apolipoprotein (apo) B, apo B67, in addition to the normal species, apo B100 and apo B48. The size of apo B67 and immunochemical studies with a panel of apo B-specific antibodies indicated that apo B67 was a truncated species of apo B that contained approximately the amino-terminal 3,000-3,100 amino acids of apo B100. Sequencing of genomic apo B clones revealed that affected family members were heterozygous for a mutant apo B allele containing a single nucleotide deletion in exon 26 (cDNA nucleotide 9327). This frameshift mutation is predicted to result in the synthesis of a truncated apo B containing 3,040 amino acids. Apo B67 is present in low levels in the plasma but is easily detectable within the very low density lipoprotein and low density lipoprotein fractions. Examination of the proband's immediate family revealed seven normolipidemic subjects and seven subjects with hypobetalipoproteinemia. In the affected subjects, the mean total and low density lipoprotein cholesterol levels were 120 and 42 mg/dl, respectively. A significantly higher mean high density lipoprotein cholesterol level was found in the affected subjects (75 vs. 55 mg/dl). We hypothesize that the elevated high density lipoprotein cholesterol levels in subjects heterozygous for the apo B67 mutation may be metabolically linked to the low levels of apo B-containing lipoproteins in their plasma. (J. Clin. Invest. 1991. 87:1748-1754.
Introduction
Within the past 3 years, investigators from several laboratories have demonstrated that familial hypobetalipoproteinemia can A portion ofthe data in this article was presented at the 1989 and 1990 Scientific Sessions of the American Heart Association.
Address reprint requests to either Dr. Welty Receivedfor publication 2 October 1990 and in revisedform 28 December 1990. be caused by a variety of apolipoprotein (apo) B gene mutations that prevent the translation of a full-length apo BI00 (1) . Several ofthese apo B gene mutations result in the synthesis of a truncated species of apo B that can be detected within the plasma lipoproteins (1) . Individuals homozygous for familial hypobetalipoproteinemia typically have extremely low low density lipoprotein (LDL) cholesterol levels, usually < 5 mg/dl (2) . Because apo B synthesis is required for intestinal absorption ofdietary fats, these homozygotes may have clinical symptoms related to malabsorption of fats and fat-soluble vitamins.
Although the absorption of dietary fats in carefully documented familial hypobetalipoproteinemia heterozygotes has not yet been rigorously examined, it is rare for these heterozygotes to report any symptoms offat malabsorption (2) . Heterozygotes typically have total plasma cholesterol levels in the range of 90-150 mg/dl, with LDL cholesterol levels in the range of 25-50 mg/dl (1) . Because of their low cholesterol levels, heterozygotes may actually be protected from the development of atherosclerotic coronary artery disease (3). Glueck and co-workers (4) have reported evidence suggesting that subjects with familial hypobetalipoproteinemia may live longer than normocholesterolemic subjects. Recently, in screening a rural midwestern population, one of the authors (Dr. Welty) identified an adult male subject who had very low cholesterol levels even though he consumed a diet rich in cholesterol and saturated fats (5) . Examination of the proband's 12 children revealed that the phenotype of hypobetalipoproteinemia was inherited in a simple Mendelian fashion. In this article, we show that the plasma of hypocholesterolemic family members contained a unique truncated species of apo B, apo B67. Apo B67 was easily detectable within the lipoproteins of the very low density lipoprotein (VLDL) and LDL fractions. Apo B67 is synthesized as a result of a single nucleotide deletion in the apo B gene. The report of this kindred and their unique apo B gene mutation is informative for several reasons. Examination of the lipoproteins of affected family members provides important support for the hypothesiL that the length of apo B is an important determinant of the buoyant density of apo B-containing lipoproteins. Based on our prior studies, we had hypothesized that the longer the apo B, the more buoyant the apo B-containing lipoproteins, presumably because longer apo B's contain more lipid-binding regions. The apo B67 mutation supports this hypothesis, in that we found that apo B67-containing lipoproteins are more buoyant than apo B3 1-and apo B37-containing lipoproteins, yet slightly more dense than apo B86-containing lipoproteins. This kindred is also interesting because affected family members have elevated high density lipoprotein (HDL) cholesterol levels, as compared with the values in population controls and unaffected family members. We hypothesize that low lev-els of apo B-containing lipoproteins in affected family members may be metabolically linked to elevated HDL cholesterol levels.
Methods
Human subjects. Cholesterol measurements were obtained in 126 subjects in a rural midwestern town. Many ofthese subjects were members of farm families who consume a diet rich in saturated fats and cholesterol. One subject, the proband of the kindred described below, had a total plasma cholesterol concentration of 151 mg/dl. Additional blood samples were taken from the proband, as well as from his 12 offspring. The presence of angina pectoris in the proband and his family was assessed by the Rose questionnaire (6) . A 12-lead electrocardiogram was performed on each family member.
Analysis of lipid levels and blood chemistry. Blood samples were obtained after the subjects had fasted for 14 h. The blood was collected into tubes containing EDTA (I mg of EDTA/ml of blood), and the plasma was immediately separated by centrifugation. Total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides were measured according to Lipid Research Clinic techniques (7) in a laboratory participating in the standardization program ofthe Centers for Disease Control, Atlanta, GA. Serum thyroxin levels, vitamin A, and vitamin E levels were determined using standard techniques. The concentrations of apo A-I and apo B in plasma were determined by radioimmunoassays.
Analysis ofdiet. The diet of the proband and his family was analyzed by a detailed questionnaire. Each individual provided a complete written record of everything they consumed during a 3-d period. No recall was involved. The total caloric intake per day, the percent carbohydrate, protein, saturated fat, monounsaturated fat and polyunsaturated fat, and cholesterol were determined using the University ofMinnesota dietary analysis computer program (8) . The height and weight of each subject were recorded, and the ratio ofthe subject's weight divided by ideal body weight was calculated (9) . The body mass index [weight in kilograms/(height in meters)2] was also calculated (9).
Isolation and characterization of lipoproteins. The VLDL (d < 1.006 g/ml), intermediate density lipoprotein (IDL)' (1.006-1.025 g/ml), LDL (1.025-1.063 g/ml), and HDL (1.063-1.21 g/ml) fractions were isolated from fresh plasma by ultracentrifugation (10) . The protein content of the lipoproteins was determined by a Lowry protein assay in which bovine serum albumin was the standard (1 1). The apolipoprotein content of each lipoprotein fraction was assessed by 3-12% gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on gels stained with 0.1% Coomassie Brilliant Blue R-250 or with silver. In some cases, the apolipoproteins separated by SDS-PAGE were electrophoretically transferred to nitrocellulose membranes for Western blotting (12, 13). For Western blots, we used a variety of previously characterized apo B-specific antibodies (12, [14] [15] [16] [17] [18] . The size of lipoprotein particles within the LDL and HDL fractions was assessed by nondenaturing gradient polyacrylamide gels, as previously described (15, 19, 20) . In some cases, the lipoproteins separated according to size by the nondenaturing gels were electrophoretically transferred to nitrocellulose membranes for Western blots (15) .
Enzymatic amplification ofDNA and DNA sequencing. The SDSpolyacrylamide gels revealed a unique truncated apo B species, apo B67, in the lipoproteins of affected family members. The size of the protein, as well as its reactivity with apo B-specific antibodies suggested that its carboxy terminus must be in the vicinity of apo B100 amino acid residues 3030-3050 (see Results). To determine the precise mutation in the apo B gene responsible for apo B67, a 1,126-base pair 1 After the mutation responsible for apo B67 had been determined, the presence of this mutation in other family members was assessed by analyzing freshly prepared lipoprotein samples for the presence ofapo B67 by SDS-PAGE.
Results
A pedigree illustrating the apo B67 kindred is shown in Fig. 1 . The proband (subject I-1) had total and LDL cholesterol levels of 151 and 47 mg/dl, respectively (Table I) to apo B67 (Fig. 4) . To determine the precise mutation accounting for apo B67, we enzymatically amplified the appropriate region ofthe apo B gene from the genomic DNA ofsubject and then subcloned it into M13 for sequencing. 4 (Fig. 5 ) was identified in both strands. This deletion is predicted to yield a single novel amino acid followed by a premature stop codon (Fig. 5) . The location of the mutation predicts that apo B67 contains 3040 amino acids.
The proband had 12 offspring. Neither the proband nor any of his children had clinical evidence ofcoronary artery disease, as judged by an electrocardiogram and the Rose questionnaire. 6 of the 12 children had hypobetalipoproteinemia, as defined by a fasting LDL cholesterol level below the 5th percentile for age-and sex-matched controls (Table I ). These six offspring were apo B67 heterozygotes, as determined by SDS-PAGE of the plasma lipoproteins. The triglyceride level in these seven subjects (the proband and the six offspring who were apo B67 heterozygotes) was remarkably low, averaging 13 mg/dl. Interestingly, the HDL cholesterol levels in affected subjects averaged 75 mg/dl, significantly higher than in unaffected family members (P < 0.01). All seven affected subjects had HDL cholesterols above the 85th percentile for age-and sex-matched controls; six of the seven had HDL cholesterol levels at or above the 95th percentile.
In every affected subject, the absolute concentration of apo B67 in plasma was low relative to that of the apo B1OO produced by the normal allele. Based upon the relative staining Figure 3 . A nondenaturing, 2-16% gradient polyacrylamide gel demonstrating the size of apo B67-containing LDL particles. A Pharmacia PAA 2/16 gel was used according to previously described methods (15, 19, 20) . Lanes I and 2, LDL of two different hypolipoproteinemic family members (I-I and 11-2); lane 3, the LDL of a normolipidemic control subject; lane 4, the LDL of an unaffected family member; lane 5, the HDL fraction of an apo B37 heterozygote (15) .
For each lane, 5-10 jig of protein was loaded; the gel was stained with silver. On Western blots, the band identified as apo B IOO particles reacted with apo B-specific antibodies whose epitopes are in the amino-terminal and carboxy-terminal portions of apo B 100 (data not shown). The band identified as apo B67 particles reacted only with antibodies whose epitopes are located between amino acids 1 and 3080, and not with the carboxy-terminal antibodies (data not shown). For lane 5, the migration of apo B37-containing particles within the HDL fraction is indicated by the bracket designated A; the migration of apo A-I-containing particles in the HDL fraction is indicated by the bracket designated B. The migration of the size standards is indicated: thyroglobulin (669,000) and ferritin (440,000).
intensities of the LDL apo B 100 and apo B67 bands on SDS-PAGE as well as the nondenaturing gels (Figs. 2 and 3) , we have estimated that the plasma concentration of apo B67 is significantly < 5% ofthe apo B l00 concentration. The distribution of apo B67 within the different lipoprotein density classes in the affected subjects in the second generation was identical to that observed in the proband (see above).
The mutation accounting for apo B67 occurs several kilobases 3' to the edited nucleotide responsible for the synthesis of apo B48. One might therefore predict that the single nucleotide deletion in the apo B67 allele would not significantly affect apo B48 synthesis. If this were the case, apo B67 heterozygotes would have two alleles producing apo B48, yet only one making apo B100. Indirect support for this hypothesis was obtained by examining the VLDL of affected and unaffected individuals. When the VLDL of four affected subjects was analyzed by SDS-PAGE, we noticed that the amount of apo B48 in the VLDL, relative to apo B100, was significantly greater in the affected subjects (Fig. 6) . We have recently observed the same increased apo B48/apo B100 ratio in the VLDL of apo B86 heterozygotes (23) .
The dietary intake of affected and unaffected family members was determined from an analysis of a 3-d diet. No statistically significant differences in the total number of calories consumed or composition ofthe diet were observed (Table  II) . Similarly, we found no difference between affected and unaffected subjects in their activity level, as judged by the estimated number of miles walked per day. However, quite unexpectedly, we found a significant difference in their relative body weight and body mass index. The unaffected family members were significantly heavier than affected family members (Table II) .
Discussion
In the past 3 years, reports by a number of investigators have made it clear that apo B gene mutations can cause familial hypobetalipoproteinemia (1) . Each of the mutations reported to date has prevented the translation ofa full-length apo B 100. Some of these mutations have resulted in the production of a truncated form of apo B that can be identified within the plasma lipoproteins. In this paper, we report a unique apo B mutation associated with familial hypobetalipoproteinemia. A single nucleotide deletion in exon 26 of the apo B gene causes the synthesis of a truncated species of apo B, apo B67. The apo B67 mutation provides important support for the hypothesis that the buoyant density of apo B-containing lipoproteins is inversely related to the length of the apo B molecule. Previously, we have hypothesized that longer apo B species tend to form less dense (i.e., more buoyant) lipoproteins because longer forms of apo B would contain more lipid-binding regions (1, 24) . The apo B67 mutation supports this hypothesis; apo B67-containing lipoproteins are, in general, more buoyant than apo B31-and apo B37-containing lipoproteins, yet slightly less buoyant than apo B86-containing lipoproteins. The density distribution ofthe various truncated apo B species that our laboratory has examined, including apo B67, is illustrated in Fig. 7 .
The absolute concentration of the truncated apo B in plasma was low in affected family members, just as has been documented in other examples of truncated apo B's associated with hypobetalipoproteinemia (1) . Whether the low levels of apo B67 are due to low synthetic rates or increased degradation rates is not yet known. Two longer truncated apo B species, apo B87 and apo B89, have been reported to bind to receptor with enhanced affinity, possibly explaining the low levels of these truncated apo B species (25, 26) . The ability of apo B67 to bind to the LDL receptor has not yet been experimentally tested. Apo B67 is predicted to contain 3,040 amino acids and contains the epitope for antibody 4G3 (16, 17) , an antibody widely used over the past 10 years for blocking the binding of LDL to the LDL receptor (Fig. 8) . However, apo B67 terminates before epitopes for several other LDL receptorblocking antibodies, before the missense mutation at residue 3500 that is associated with defective binding of LDL to the LDL receptor, and before the two short positively charged amino acid sequences that have been hypothesized to be involved in receptor binding (Fig. 8) . Because apo B67 does not contain these latter domains, it is our hypothesis that apo B67, like apo B37 (27), would not bind to the LDL receptor. We plan to purify apo B67-containing lipoproteins to test this possibility directly. The affected heterozygotes in this family have consented to lipoprotein turnover studies on the metabolic ward, and studies are being planned to search for the cause of the low levels of apo B67 in their plasma. The significantly lower body weight in the affected subjects, compared with the unaffected subjects, was an unexpected finding. This result could be explained by postulating some degree of intestinal malabsorption. Counter to this hypothesis is the fact that the affected subjects were free of clinical symptoms of (Fig. 6) ; these data are consistent with the hypothesis that apo B67 heterozygotes make normal amounts ofapo B48, yet half-normal amounts of apo B 100. Based on these arguments, we are skeptical about the possibility ofintestinal malabsorption. It is possible that the significantly lower weight of affected subjects is the result of chance. This issue needs to be investigated further in other kindreds with hypobetalipoproteinemia. An interesting aspect of this kindred is the fact that every affected subject had a high HDL cholesterol level. Six of the seven heterozygotes had an HDL cholesterol level at or exceeding the 95th percentile for age-and sex-matched controls. High HDL levels have previously been observed in all four apo B3 1 heterozygotes (24) and five of the six apo B46 heterozygotes (28) , although the observation was not discussed in the description of those kindreds. However, high HDL cholesterol levels have not always been observed in the affected members of kindreds with hypobetalipoproteinemia heterozygotes (29) . It is possible that another inherited trait or traits govern the ability to "respond" to low apo B levels with high HDL cholesterol levels.
The metabolic basis for the high HDL cholesterol levels in heterozygotes for hypobetalipoproteinemia requires further analysis. One possibility is that the paucity ofapo B-containing lipoproteins in the plasma retards the cholesteryl ester transfer protein-mediated transfer ofHDL cholesterol to more buoyant lipoproteins. If this were the mechanism for the high HDL cholesterol levels, one might expect to find an accumulation of HDL2 in their plasma, as occurs in a deficiency of cholesterol ester transfer protein, where there is a defect in the transfer of HDL2 cholesterol to apo B-containing lipoproteins (30). However, in preliminary studies, we have found elevated HDL3 and normal HDL2 levels in two apo B67 heterozygotes, as determined by dextran sulfate precipitation. Both subject 1-1 and subject 11-2 had normal HDL2 levels, but significantly elevated HDL3 levels. The apo A-I, but not the apo A-II, levels were elevated in these two subjects (F. Welty and M. Cheung, unpublished observations). The same pattern-a disproportionate amount ofHDL3-has been reported in other subjects with well-documented cases of hypobetalipoproteinemia (15, 31) . Another possibility is that the high HDL cholesterol levels might be a consequence of altered metabolism of triglyceriderich lipoproteins. Hypoalphalipoproteinemia is frequently observed in subjects with hypertriglyceridemia. Our affected subjects had hyperalphalipoproteinemia associated with extraordinarily low plasma triglyceride levels. Recently, Ginsberg and co-workers (32) have reported that normotriglyceridemic subjects with hypoalphalipoproteinemia tend to have a high apo A-I fractional catabolic rate as well as a high LDL-apo B production rate. They suggested the possibility that a portion of the increased heart disease risk in subjects with hypoalphalipoproteinemia is due to elevated LDL-apo B production rate (32) . We suggest that hypobetalipoproteinemia may represent the other end of the spectrum from the subjects characterized by Ginsberg and co-workers (32) . Perhaps heterozygotes for hypobetalipoproteinemia, whose LDL-apo B production rates are almost certainly very low (33), have a decreased catabolic rate for apo A-I. We plan to test this hypothesis by performing apo B100 and apo A-I turnover studies in affected subjects. 
